Furthermore, IGF2BP1 can promote the progression of CRC, osteosarcoma, intrahepatic cholangiocarcinoma, and clear-cell RCC by stabilizing the mRNAs of factors that enhance glucose metabolism, including those of SOGA1, ERRa, NFAT5, and LDHA.97, 98, 99, 100 In summary, IGF2BP1-mediated m6A modification plays a multifaceted role in the TME, acting as a key driver in tumorigenesis and cancer progression. This evidence concerns the gene IGF2BP1 and colorectal carcinoma.